14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
SRZN vs PYPD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (31.1/100 SELL vs. 33.2/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SRZN currently prints a higher short-term Unified Composite Score (33.2/100 SELL vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -485.4% operating margin) and revenue trajectory (+0.0% vs. +408.6% YoY).
Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both SRZN (33.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs PYPD. Trailing 12-month operating profitability (SRZN -485.4% vs PYPD 0.0%) and valuation multiples (SRZN N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SRZN vs PYPD Key Questions & Quantitative Answers
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (31.1/100 SELL vs. 33.2/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SRZN currently prints a higher short-term Unified Composite Score (33.2/100 SELL vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -485.4% operating margin) and revenue trajectory (+0.0% vs. +408.6% YoY). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both SRZN (33.2/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRZN generates $11M in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.
SRZN screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus PYPD (-243.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.